-
(CELC.O) rose 7.84% amid mixed technical signals, showing bullish momentum but unclear trend direction.
- Analysts from Needham and HC Wainwright reiterated Strong Buy ratings, with 80-83% historical accuracy, aligning with recent price gains.
- Retail investors showed modest support (51.41% inflow), while institutional flows remained negative, reflecting cautious institutional sentiment.
- U.S. vaccine policy shifts and Trump-era uranium mining focus may indirectly impact Celcuity’s diagnostics sector positioning.
- Technical indicators showed 3 bullish signals (including MACD Death Cross) but a bearish Marubozu White reversal risk, suggesting volatile indecision.
Comments
No comments yet